Black Diamond Therapeutics, Inc. reported a significant decline in financial performance for the first quarter of 2026, with a net loss of $9.0 million compared to a net income of $56.5 million in the same period of 2025. The company did not record any license revenue during this quarter, a stark contrast to the $70.0 million received in the previous year from a licensing agreement with Servier Pharmaceuticals for the development of BDTX-4933. Total operating expenses decreased to $11.3 million from $15.5 million, primarily due to reduced research and development costs, which fell to $7.0 million from $10.5 million.
The company's total assets as of March 31, 2026, were reported at $132.9 million, a decrease from $143.0 million at the end of 2025. Cash and cash equivalents increased to $30.1 million from $21.0 million, while investments decreased to $88.2 million from $107.7 million. The accumulated deficit grew to $473.8 million, reflecting the ongoing challenges faced by the company in achieving profitability. The decrease in total liabilities to $28.6 million from $30.8 million was attributed to a reduction in accrued expenses and other current liabilities.
Strategically, Black Diamond Therapeutics has focused on advancing its lead clinical-stage program, silevertinib, which targets oncogenic mutations in non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The company initiated a randomized Phase 2 trial for silevertinib in newly diagnosed patients with EGFRvIII-positive GBM in May 2026. Additionally, the company is exploring potential partnerships to further develop silevertinib and has made progress in its clinical trials, with encouraging results reported for its NSCLC program.
As of March 31, 2026, Black Diamond Therapeutics had approximately $118.3 million in cash, cash equivalents, and investments, which the company believes will fund its operations into the second half of 2028. However, the company anticipates needing additional capital to support ongoing clinical trials and operational expenses. The outlook remains cautious, with management highlighting the need for substantial funding to continue its growth strategy and the potential for delays or reductions in research and development activities if financing is not secured.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.